Lumida
/ELV
⌘K
Elevance Health Inc

Elevance Health Inc

ELV
$373.11USD+0.07%+0.26 today

MARKET CAP

80.9B

P/E (TTM)

12.7x

FWD P/E

13.4x

DAY RANGE

$365 – $378

52W RANGE

$274
$436

AI Summary

Stalk
TrimMedium

ELV is in a Stage 3 distribution phase with declining moving averages and a broken support structure, establishing a bearish medium-term bias. However, extreme oversold readings and significant extension below moving averages caution against immediate selling. Optimal execution involves waiting for a pullback and rejection at prior support turned resistance—namely the 9/21 EMAs and 50 SMA—before initiating new short positions.

  • Q1 adjusted EPS $12.58 drove full-year guide to ≥$26.75 on favorable claims
  • Membership grew to 45.4M, expects ~1.2M additional members by Q2 end
  • Medicaid/Medicare rates lag elevated acuity, compressing margins
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Elevance Health, Inc. (NYSE: ELV) is a leading player in the health benefits sector, adeptly offering a comprehensive range of integrated care solutions across commercial, Medicaid, and Medicare markets. The company places significant emphasis on affordability, simplicity, and the integration of advanced technologies, particularly artificial intelligence (AI), to drive operational efficiencies and improve patient care outcomes. This positions Elevance strategically within the overarching themes of healthcare transformation and the growing demand for value-based care.

Bull says

  • Q1 adjusted EPS $12.58 drove full-year guide to ≥$26.75 on favorable claims
  • Membership grew to 45.4M, expects ~1.2M additional members by Q2 end
  • Deploying $1.1B to repurchase 3.7M shares, signaling capital confidence
  • Investing >$1B in AI to boost operational efficiency and member engagement
  • Favorable rate sensitivity (1.09) supports margins amid rising interest rates
  • Strong factor profile with high earnings yield, dividend yield, and momentum

Bear says

  • Medicaid/Medicare rates lag elevated acuity, compressing margins
  • Negative profitability trend from ongoing elevated medical cost pressures
  • Anticipated ~750k Medicaid membership decline in 2026 due to re-verifications
  • Expiration of ACA subsidies risks material ACA market contraction
  • Low institutional ownership and rising short interest reflect investor caution
  • Factor profile shows weak growth, high volatility, and elevated risk

Investment themes with ELV

High Dividend Yield +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 07-15-2026neutral

Transcript signals

Read full transcript analysis ›